104 related articles for article (PubMed ID: 23611227)
1. [High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review].
Jiang JH; Fang BM; Xu YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):162-3. PubMed ID: 23611227
[No Abstract] [Full Text] [Related]
2. Primary central nervous system lymphoma: recent progress, many remaining questions.
Swinnen LJ
Curr Opin Oncol; 2009 Sep; 21(5):393-6. PubMed ID: 19593137
[TBL] [Abstract][Full Text] [Related]
3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.
Wolf T; Kiderlen T; Atta J; Stephan C; Kann G; Brodt HR; Brandts C
Infection; 2014 Apr; 42(2):445-7. PubMed ID: 24442720
[No Abstract] [Full Text] [Related]
5. Primary central nervous system lymphoma with testicular metastasis.
Liu XJ; Zhao JZ; Li G; Ye X; Yan PX
Clin Neurol Neurosurg; 2012 Jan; 114(1):80-3. PubMed ID: 21871714
[No Abstract] [Full Text] [Related]
6. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
7. Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.
Lukas RV; Gondi V; Stupp R; Raizer JJ
Oncology (Williston Park); 2018 Feb; 32(2):e11-e19. PubMed ID: 29492949
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary CNS lymphoma.
Schmitz N
Blood; 2015 Feb; 125(9):1360-1. PubMed ID: 25721041
[TBL] [Abstract][Full Text] [Related]
11. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
12. [Primary central nervous lymphoma: what is the role for radiotherapy?].
Bellefqih S; Mezouri I; Khalil J; Bazine A; Diakité A; El Kacimi H; Kebdani T; Benjaafar N
Cancer Radiother; 2014 Nov; 18(7):685-92. PubMed ID: 25451676
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Huang HC; Cheng AL; Lin CW; Kuo SH
Ann Hematol; 2013 Jul; 92(7):989-92. PubMed ID: 23242476
[No Abstract] [Full Text] [Related]
15. Primary central nervous system lymphoma: essential points in diagnosis and management.
Paydas S
Med Oncol; 2017 Apr; 34(4):61. PubMed ID: 28315229
[TBL] [Abstract][Full Text] [Related]
16. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma-directed conditioning for aggressive lymphoma.
Sureda A
Lancet Oncol; 2014 Jun; 15(7):678-9. PubMed ID: 24827807
[No Abstract] [Full Text] [Related]
18. Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
Waibel Pachinger C; Rosselet A; Berthouzoz S; Luthi F; Ketterer N
Hematol Oncol; 2012 Dec; 30(4):216-8. PubMed ID: 22287477
[No Abstract] [Full Text] [Related]
19. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
[TBL] [Abstract][Full Text] [Related]
20. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
